Prognostic value of ERCC1, RRM1, and TS proteins in patients with resected non-small cell lung cancer

被引:14
作者
He, Yu-Wen [1 ]
Zhao, Mei-Ling [2 ]
Yang, Xin-Yun [1 ]
Zeng, Jun [3 ]
Deng, Qiu-Hua [1 ]
He, Jian-Xing [2 ]
机构
[1] Guangzhou Med Univ, Dept Pharm, Affiliated Hosp 1, Guangzhou 510120, Guangdong, Peoples R China
[2] Guangzhou Med Univ, State Key Lab Resp Dis, Affiliated Hosp 1, Dept Thorac Surg, Guangzhou 510120, Guangdong, Peoples R China
[3] Guangzhou Med Univ, Dept Med Genet & Cell Biol, Guangzhou 510120, Guangdong, Peoples R China
关键词
Non-small cell lung cancer; Excision repair cross-complementation group 1; Ribonucleotide reductase M1; Thymidylate synthase; Chemotherapy; THYMIDYLATE SYNTHASE; DNA-REPAIR; PREDICTIVE BIOMARKERS; EXPRESSION; SURVIVAL; REDUCTASE; CHEMOTHERAPY; EXCISION; MARKERS;
D O I
10.1007/s00280-015-2714-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recent clinical trials showed that expression of excision repair cross-complementation group 1 (ERCC1), ribonucleotide reductase M1 (RRM1), and thymidylate synthase (TS) proteins was able to predict the effects of non-small cell lung cancer (NSCLC) to chemotherapy. However, it remains unknown whether the adjuvant chemotherapy based on expression of the three proteins has survival significance in Chinese NSCLC patients. We investigated 128 Chinese patients receiving chemotherapy after tumor resection for expression of these proteins using immunohistochemistry. Based on protein expression, patients were assigned to two groups for different adjuvant chemotherapy regimes. The disease-free survival (DFS) data were collected and analyzed using Kaplan-Meier curves and Cox models. We found that DFS of these patients with carboplatin and a third-generation agent (gemcitabine or pemetrexed) stratified by protein expression showed no statistical difference between individual treatment versus non-individuation treatment analyzed using Kaplan-Meier method (P = 0.143, median 23.9 vs. 30.8 months). Furthermore, the multivariate analysis showed that histology and tumor stages were independent predictors for DFS in these patients. The results suggest that chemotherapy based on ERCC1, RRM1, and TS expression did not have significant impact on DFS of patients with resection of NSCLC.
引用
收藏
页码:861 / 867
页数:7
相关论文
共 50 条
  • [1] Prognostic value of ERCC1, RRM1, and TS proteins in patients with resected non-small cell lung cancer
    Yu-Wen He
    Mei-Ling Zhao
    Xin-Yun Yang
    Jun Zeng
    Qiu-Hua Deng
    Jian-Xing He
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 861 - 867
  • [2] Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer
    Lafuente-Sanchis, A.
    Zuniga, A.
    Galbis, J. M.
    Cremades, A.
    Estors, M.
    Martinez-Hernandez, N. J.
    Carretero, J.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2016, 18 (08) : 798 - 804
  • [3] ERCC1 and RRM1 genes in lung cancer
    Carvalho, Lina
    Silva, Antonio
    Andrade, Claudia
    Barroso, Claudia
    Farinha, Claudia
    Fernandes, Jose Carlos
    Landeiro, Raquel
    REVISTA PORTUGUESA DE PNEUMOLOGIA, 2009, 15 (04) : 683 - 696
  • [4] Prognostic Significance of ERCC1, RRM1 and BRCA1 in Surgically-treated Patients with Non-small Cell Lung Cancer
    Pesta, Martin
    Kulda, Vlastimil
    Fiala, Ondrej
    Safranek, Jarmil
    Topolcan, Ondrej
    Krakorova, Gabriela
    Cerny, Radim
    Pesek, Milos
    ANTICANCER RESEARCH, 2012, 32 (11) : 5003 - 5010
  • [5] Prognostic significance of the mRNA expression of ERCC1, RRM1, TUBB3 and TYMS genes in patients with non-small cell lung cancer
    Sun, Shengjie
    Shi, Weiwei
    Wu, Zhiyong
    Zhang, Guoqing
    Yang, Bo
    Jiao, Shunchang
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2015, 10 (03) : 937 - 941
  • [6] Prognostic value of ERCC1 and RRM1 in NSCLC patients with smoking history or not
    Sun, Jiangtao
    Song, Kaifang
    Yuan, Xiang
    Gao, Shegan
    Feng, Xiaoshan
    Yang, Bo
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2017, 10 (05): : 5889 - 5894
  • [7] Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy
    Zhao, Hui
    Zhang, Huawei
    Du, Yonghai
    Gu, Xiaomeng
    TUMOR BIOLOGY, 2014, 35 (12) : 12679 - 12688
  • [8] ERCC1 and RRM1-predictive vs. prognostic roles in non-small cell lung cancer (NSCLC)
    Simon, George R.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S51 - S53
  • [9] ERCC1 and the efficacy of cisplatin in patients with resected non-small cell lung cancer
    Li, Chunhong
    Liu, Meiyan
    Yan, An
    Liu, Wei
    Hou, Junjun
    Cai, Li
    Dong, Xiaoqun
    TUMOR BIOLOGY, 2014, 35 (12) : 12707 - 12712
  • [10] ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer
    Su, Chunxia
    Zhou, Songwen
    Zhang, Ling
    Ren, Shengxiang
    Xu, Jianfang
    Zhang, Jie
    Lv, Meijun
    Zhang, Jie
    Zhou, Caicun
    MEDICAL ONCOLOGY, 2011, 28 (04) : 1411 - 1417